PD‐1 blockade using pembrolizumab in adolescent and young adult patients with advanced bone and soft tissue sarcoma
Authors:
Open Access
- 13 December 2020
- journal article
- research article
- Published by Wiley in Cancer Reports
- Vol. 4 (2) , e1327
Abstract
Background: Sarcomas represent 10%–15% of cancers in adolescent and young adult (AYA) patients, and survival for those with metastatic disease or relapse is poor. Immunotherapy with checkpoint inhibition has improved outcomes in multiple tumor types, but data in advanced sarcomas, particularly within the AYA population, are limited.Aim: We aim to evaluate response and toxicity for AYA patients with sarcoma treated with pembrolizumab.Methods and results: We retrospectively reviewed AYA patients with advanced bone and soft tissue sarcoma who received self‐funded pembrolizumab between May 2015 and January 2019. Eighteen patients were identified. One patient with Ewing sarcoma had a sustained complete response to therapy. Two patients with alveolar soft part sarcoma received a clinical benefit from pembrolizumab: one had a radiological partial response with an excellent clinical response and one patient achieved stable disease. Four patients died of disease prior to first scheduled assessment and thus were not evaluable. The remaining eleven patients had progressive disease.Conclusion: The role of immunotherapy in AYA sarcoma warrants further investigation. Biomarkers of response need to be further evaluated in order to guide patient selection.Keywords
Funding Information
- Cancer Institute NSW
- NSW Health
- University of Sydney
- Vodafone Foundation
This publication has 23 references indexed in Scilit:
- Response to anti-PD1 therapy with nivolumab in metastatic sarcomasClinical Sarcoma Research, 2016
- Analysis of protein-coding genetic variation in 60,706 humansNature, 2016
- MultiDimensional ClinOmics for Precision Therapy of Children and Adolescent Young Adults with Relapsed and Refractory Cancer: A Report from the Center for Cancer ResearchClinical Cancer Research, 2016
- Programmed cell death-1 blockade in recurrent disseminated Ewing sarcomaJournal of Hematology & Oncology, 2016
- Chemotherapy Use, Performance Status, and Quality of Life at the End of LifeJAMA Oncology, 2015
- PD-L1 and CD8+PD1+ lymphocytes exist as targets in the pediatric tumor microenvironment for immunomodulatory therapyOncoImmunology, 2015
- A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial SarcomaSarcoma, 2013
- Performance status is the most powerful risk factor for early death among patients with advanced soft tissue sarcomaBritish Journal of Cancer, 2011
- Latest Estimates of Survival Rates of the 24 Most Common Cancers in Adolescent and Young Adult AmericansJournal of Adolescent and Young Adult Oncology, 2011
- Starting an Adolescent and Young Adult Program: Some Success Stories and Some Obstacles to OvercomeJournal of Clinical Oncology, 2010